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INTRODUCTION
The role of inflammation in the development of atheroscle-
rosis can be considered proven (Ross, 1999; Fuster and
Sanz, 2008; Virani et al., 2008). The various impacts of the
traditional risk factors (RF) for cardiovascular diseases
(CVD) — smoking, arterial hypertension (AH), dyslipide-
mia, obesity, etc. — on blood vessels are determined by the
local inflammatory reactions in the vessels and the systemic
inflammatory reaction (Fuster and Sanz, 2008; Ikonomidis
at al., 2008).
Numerous body cells and tissues, especially monocytes and
fatty tissues, express different mediators of inflammation in
response to various irritants and changes in the body (in-
cluding CVD RF) that stimulate both the local inflamma-
tory reactions in blood vessels and the systemic inflamma-
tory response (El-Mennyar, 2008; Virani et al., 2008).
Various inflammatory factors have been studied in relation
to atherosclerosis and chronic inflammatory reactions, in-
cluding C-reactive protein (CRP), the interleukins (IL6,
IL8, IL18, etc.), fibrinogen, soluble intracellular and vascu-
lar cell adhesion molecules, tumour necrosis factor alpha
(TNF-), macrophage and monocyte chemoattractant pro-
tein, serum amyloid A, and leptin. Many inflammatory
markers are recognised as independent CVD RF
(El-Mennyar, 2008; Miles et al., 2008). The assessment of
inflammatory markers yields valuable information on the
development of atherosclerosis. Recently, the inflammatory
reactions linked to obesity have been intensively studied,
especially in relation to metabolic syndrome (Caglayan et
al., 2005; Calabro and Yeh, 2008; Calabro et al., 2008).
Visceral obesity and metabolic syndrome are linked not
only by adverse changes in lipid and glucose metabolism,
but also by a pronounced inflammatory reaction. Fatty tis-
sue is an active organ that produces cytokines, chemokines,
and hormone-like substances (Caglayan et al., 2005;
Gimeno and Klaman, 2005; Calabro and Yeh, 2008;
Calabro et al., 2008). The activity of inflammatory markers
is elevated in obese subjects, and also facilitates the devel-
opment of obesity-linked metabolic and cardiovascular
complications (Gimeno and Klaman, 2005; Calabro et al.,
2008).
The most significant and extensively researched inflamma-
tory markers are C-reactive protein (CRP), several inter-
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The inflammatory reaction plays an important role in the development of atherosclerosis. The clin-
ical significance of the main inflammatory markers — C-reactive protein (CRP), interleukin 6 (IL6),
tumour necrosis factor alpha (TNF-), plasminogen activator inhibitor 1 (PAI1), etc. — has not
been fully established. CRP, IL6, TNF-, and PAI1 were assessed in 100 patients in terms of cer-
tain clinical indicators (sex, obesity indicators, blood pressure, and heart rate), total cholesterol
(TC), low-density lipoprotein–cholesterol (LDL–C), high-density lipoprotein–cholesterol (HDL–C),
triglycerides (TG), glucose, insulin, homeostasis model assessment of insulin resistance
(HOMA-IR), adiponectin, and leptin levels. CRP and PAI1 levels were elevated in subjects with in-
creased body mass index (BMI) and waist circumference. CRP correlated positively with indica-
tors of carbohydrate metabolism and negatively with TC, HDL–C, and adiponectin. PAI1
correlated positively with insulin levels, HOMA-IR, leptin, and TG, but negatively with HDL–C. IL6
correlated negatively with TC, but TNF- correlated negatively with HDL–C. Both IL6 and TNF-
correlated positively with leptin levels. TNF- correlated with TG levels and the indicators of car-
bohydrate metabolism only in women. CRP and PAI1 are the most sensitive inflammatory mark-
ers; their levels were higher in adipose subjects.
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leukins (IL6, IL18, etc.), and TNF-. Plasminogen activator
inhibitor 1 (PAI1) is also associated with the inflammatory
response. These inflammatory markers reflect different in-
flammatory processes. However, they are also mutually
interlinked to a certain extent and associated with traditional
RF (Espinola-Klein et al., 2005; Gimeno and Klaman,
2005; Kahn et al., 2005; Ikonomidis et al., 2008). CRP is
the most extensively studied inflammatory marker. It not
only reflects the total inflammatory reaction in the body
very well, but also influences the impairment of the endo-
thelium itself (Kahn et al., 2005; Nilson 2005; Ikonomidis
et al., 2008). The expression of CRP is stimulated by other
inflammatory markers, such as TNF- and IL6, which also
have an adverse impact on endothelial function. TNF- fa-
cilitates insulin resistance (Berg and Scherer, 2005;
Caglayan et al., 2005; Matsuzawa, 2006) and correlates
with glucose and insulin levels (Calabro and Yeh, 2008).
Levels of IL6 also correlate with insulin resistance (Gimeno
and Klaman, 2005; Calabro and Yeh, 2008). TNF- is
closely linked to dyslipidemia, because by reducing the ac-
tivity of lipoprotein lipase, it stimulates the elevation of
triglyceride (TG) levels and reduces high-density lipopro-
tein–cholesterol (HDL–C) (Rosenson, 2005).
PAI1, a regulator of the endogenous fibrinolytic system,
which is predominantly expressed in the vessel walls, plays
a significant role in the development of thrombotic compli-
cations, remodelling of artery walls, and CVD (Gimeno and
Klaman, 2005; Taeve et al., 2005). The expression of PAI1
in the endothelium is stimulated by the inflammatory re-
sponse and elevated glucose and insulin levels in the blood,
and correlates with levels of IL6 and TNF- (Rosenson,
2005; Taeve et al., 2005). Previous studies have reported
contradictory findings regarding the role of IL6 and TNF-
in the development of CVD, especially in terms of their
links to traditional RF (Alberti et al., 2005; El-Menyar,
2008; Ikonomidis et al., 2008).
Because of the recognised role of inflammation in the de-
velopment of atherosclerosis, research into inflammatory
markers is considered very promising in this context (El-
Menyar, 2008; Espinola-Klein et al., 2008; Fuster and Sanz,
2008; Ikonomidis et al., 2008). The investigation of these
markers should allow us to define more accurately the
course and severity of atherosclerosis, and assist us in as-
sessing CVD risk (Alberti et al., 2005; El-Menyar, 2008;
Ikonomidis et al., 2008). The assessment of inflammatory
markers could be especially valuable in the diagnosis of
subclinical atherosclerosis (Nilson, 2005; El-Menyar, 2008;
Ikonomidis et al., 2008). Changes in inflammatory markers
differ over the various stages of atherosclerosis; conse-
quently, the simultaneous assessment of many markers is of
great value. The larger the number of altered markers, the
greater the risk of CVD (Ikonomidis et al., 2008). Regard-
less of the recognised and important role of inflammatory
markers in the assessment of CVD risk, their clinical mean-
ing requires a more precise definition (Ikonomidis et al.,
2008).
The objective of this work was to assess the connection be-
tween four inflammatory markers (CRP, IL6, TNF-, and
PAI1) and the clinical RF of CVD, indicators of lipid and
carbohydrate metabolism, adiponectin, and leptin.
MATERIALS AND METHODS
One hundred patients were analysed, 48 of whom were out-
patients without clinical signs of CVD and 52 of whom
were treated on an inpatient basis, predominantly for AH
(48 patients) or for coronary heart disease or type 2 diabetes
mellitus (four patients). All patients gave their informed
consent to the protocol, which was approved by the local
Medical Ethics Committee of Latvian Institute of Cardiol-
ogy of University of Latvia for Medical Research. The aver-
age patient age (±SD) was 52.4 ± 11.1 years, and 41% were
male. Plasma levels of CRP (mg/mL) and IL6 (pg/mL),
TNF- (pg/mL), and PAI1 (ng/mL) levels in the blood were
assessed in all patients. Blood samples (5 mL) for cytokine
analysis were collected after a 12 h fast and a 30 min resting
period in the supine position. They were immediately cen-
trifuged at 4 °C for 20 min at 1600  g to separate the se-
rum, and the samples were stored at –70 °C. xMAP multi-
plex immunobead assay technology was used to measure
TNF-, IL6, leptin, PAI1, and adiponectin with a Luminex
200 analyser (Luminex Corp., Austin, TX). To quantify in-
sulin resistance, we used the homeostasis model assessment
of insulin resistance (HOMA-IR = [fasting glucose  fasting
insulin]/22.5). The HOMA-IR values have been shown to
correlate well with values obtained using the “gold stan-
dard” clamp technique (Bonora et al., 2000). Fasting con-
centrations of lipids, insulin, homocysteine, CRP, and glu-
cose were analysed using standard methods.
These markers were assessed separately in male and female
patients, and in patients with elevated BMI ( 30 kg/m2)
and high waist circumference (WC;  102 cm for men and 
88 cm for women). After the data were confirmed to have a
normal distribution, statistical differences between the
abovementioned groups were assessed by one-way analysis
of variance using Fisher’s multiple comparison test. Data
were recorded as the mean ± SD, and two-tailed values of
P < 0.05 were considered significant. Using Pearson’s cor-
relation coefficient, we analysed the correlations between
inflammatory markers and patient sex, age, adiposity indi-
cators, systolic and diastolic blood pressures (SBP and
DBP, respectively), heart rate (HR), total cholesterol (TC),
low-density lipoprotein–cholesterol (LDL–C), HDL–C, TG,
glucose, insulin, adiponectin, and leptin levels in blood
plasma and the HOMA-IR index.
RESULTS
The values obtained for the analysed inflammatory markers
are listed in Table 1 according to patient sex and obesity in-
dicators.
No significant sex-based differences in inflammatory mark-
ers were observed. In obese patients (those with increased
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BMI and WC), elevated CRP and PAI1 were observed. An
increasing trend in TNF- (P = 0.081) was observed in pa-
tients with high BMI.
Table 2 lists the correlations between the inflammatory
markers and sex, obesity indicators, blood pressure, and
HR. It follows from the data in Table 2 that CRP correlates
positively with WC and BMI in the total group, and that
these correlations were also significant when analysed indi-
vidually in each sex. IL6 did not correlate significantly with
age, obesity indicators, blood pressure, or HR in either the
total group or each sex. TNF- did not correlate signifi-
cantly with these clinical indicators in the total group, but
their analysis in each sex showed a significant negative cor-
relation between TNF- and HR only in men, and a positive
correlation between TNF- and the obesity indicators (WC
and BMI) only in women. PAI1 correlated positively with
WC and BMI in both the total group and separately in each
sex.
The correlations between the studied inflammatory markers
and the lipid and carbohydrate metabolism indicators,
adiponectin, and leptin are listed in Table 3. PAI1 correlated
significantly negatively with HDL–C and significantly posi-
T a b l e 1
LEVELS OF INFLAMMATORY MARKERS (± SD) IN THE TOTAL GROUP ACCORDING TO SEX AND OBESITY INDICATORS
Total group Sex BMI Waist circumference





































































BMI, body mass index; CRP, C-reactive protein; IL6, interleukin 6; TNF-, tumour necrosis factor alpha; PAI1, plasminogen activator inhibitor 1; P, signifi-
cance of diference
T a b l e 2
CORRELATIONS BETWEEN INFLAMMATORY MAKERS AND CLINICAL INDICATORS IN THE TOTAL GROUP (T) AND SEPARATELY IN
MEN AND WOMEN





















































































































































































BMI, body mass index; CRP, C-reactive protein; IL6, interleukin 6; TNF-, tumour necrosis factor alpha; PAI1, plasminogen activator inhibitor 1; WC,
waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; P, significance of correlation
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tively with TG. CRP correlated negatively with HDL–C and
TC. IL6 correlated negatively only with TC, TNF- corre-
lated negatively with HDL–C IL6, TNF-, and PAI1 corre-
lated positively with leptin, but CRP correlated negatively
with adiponectin. PAI1 also tended to correlate with
adiponectin, CRP, and leptin, but not significantly. When
the analysis was performed separately for each sex, CRP
correlated significantly with leptin in women. TNF- also
correlated with HDL-C and TG only in women.
CRP correlated positively with all the studied indicators of
carbohydrate metabolism, but PAI1 correlated only with in-
sulin levels and HOMA-IR. IL6 and TNF- did not corre-
late with these indicators. In women, a significant mutual
correlation was observed between all the indicators of car-
bohydrate metabolism: serum glucose, insulin, and the
HOMA-IR index.
DISCUSSION
Although the results of previous studies (Khera et al., 2005;
Saltevo et al., 2008) indicate that CRP levels are higher in
women, especially in women with metabolic syndrome, we
observed no significant sex-specific changes in or correla-
tions between CRP, IL6, TNF-, and PAI1. Among the
studied inflammatory markers, only CRP and PAI1 were el-
evated in obese patients and correlated with BMI and WC.
IL6 and TNF- were not significantly altered in obese pa-
tients. Previous studies report increased CRP (Berg and
Scherer, 2005) and PAI-1 (Taeve et al., 2005) in adipose
patients, but also increased IL6 and TNF- (Gimeno and
Klaman, 2005; Rosenson, 2005; Calabro and Yeh, 2008).
We observed a correlation between TNF- and obesity only
in women. Our data indicate that CRP and PAI1 are the
most sensitive markers of CVD risk, especially in obese pa-
tients. In women, the assessment of TNF- could also be
significant.
Although previous studies have reported correlations be-
tween CRP (Espinola-Klein et al., 2008) IL6 (Miles et al.,
2008) and even PAI1 ((Bilgili et al., 2008) and blood pres-
sure, we observed no correlation between inflammatory
markers and SBP, DBP, or HR.
According to the literature, the links between inflammatory
markers and lipid levels are indirect and complicated. Only
TNF- directly reduces the activity of lipoprotein lipase,
and stimulates an increase in TG, a reduction in HDL–C,
and the development of small, dense LDL particles
(Rosenson, 2005).
When assessing the correlation between inflammatory
markers and lipids, we found that CRP was inversely corre-
T a b l e 3
CORRELATIONS BETWEEN INFLAMMATORY MARKERS AND LIPIDS, INDICATORS OF CARBOHYDRATE METABOLISM, LEPTIN, AND
ADIPONECTIN IN THE TOTAL GROUP (T) AND SEPARATELY IN MEN AND WOMEN























































































































































































































































TC, total cholesterol; LDL–C, low-density lipoprotein–cholesterol; HDL–C, high-density lipoprotein–cholesterol; TG, triglycerides; BMI, body mass index;
CRP, C-reactive protein; IL6, interleukin 6; TNF-, tumour necrosis factor alpha; PAI1, plasminogen activator inhibitor 1; WC, waist circumference; SBP,
systolic blood pressure; DBP, diastolic blood pressure; P, significance of correlation
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lated with TC and HDL–C in the whole group, whereas IL6
correlated inversely only with TC. TNF- correlated nega-
tively only with HDL–C. CRP and IL-6 tended to correlate
negatively with LDL–C. The link between these two in-
flammatory markers and seemingly favourable anti-
atherogenic TC and LDL–C changes, and with a simulta-
neous unfavourable reduction in serum HDC–L, is evidence
of the complex association between inflammation and
lipids. Furthermore, in patients with diabetes mellitus and
metabolic syndrome, dyslipidemia is characterised not by
increased LDL–C, but by the development of small, dense
LDL–C particles. PAI1 exhibited a significant negative cor-
relation with HDL–C, but no direct correlation with TG lev-
els. Therefore, the link between PAI1 and atherogenic
dyslipidemia (increased TG and reduced HDL–C) was most
pronounced. Although we observed no correlation between
TNF- and TG levels in the total group, we identified this
correlation in women. Previous studies have also demon-
strated a link between TNF- and atherogenic dyslipidemia
(Rosenson, 2005). The negative correlation between CRP
and HDL–C supports the extensively debated anti-inflam-
matory activity of HDL–C (Alber et al. 2008; Florentin et
al., 2008). Our observations show that only HDL–C had a
frequent and pronounced inverse correlation with the in-
flammatory markers CRP and TNF-, and with PAI1. This
finding confirms the proposition that HDL–C is an inde-
pendent CVD RF with anti-inflammatory activity (Alber et
al. 2008; Florentin et al., 2008). HDLP–C showed no corre-
lation only with IL6, and IL6 showed the least pronounced
correlations with lipids (we observed only a negative corre-
lation with TC).
The correlation between the indicators of carbohydrate me-
tabolism and the inflammatory markers was most stable for
CRP (which correlated with glucose, insulin, and
HOMA-IR), whereas PAI1 correlated only with insulin lev-
els and HOMA-IR. Previous studies report that TNF- fa-
cilitates insulin resistance (Rosenson, 2005; Pi-Sinyer,
2006) and correlates with glucose and insulin levels
(Calabro and Yeh, 2008). However, we observed no corre-
lation between TNF- and any of these indicators. Al-
though no correlation was observed between TNF- and the
indicators of carbohydrate metabolism in the total group, we
found a correlation between TNF- and all three indicators
in women. We also found no link between IL6 and glucose
metabolism or insulin resistance, although these are re-
ported in the literature (Gimeno and Klaman, 2005; Calabro
and Yeh, 2008).
The pronounced correlation between CRP and the indicators
of glucose metabolism supports the proposition that the in-
creased CRP levels in patients with metabolic syndrome are
associated with a risk of developing type 2 diabetes mellitus
(Nilson, 2005).
Of the two basic adipokines (adiponectin and leptin) exam-
ined, leptin, which is itself recognised as a factor that stimu-
lates inflammation, had a pronounced positive correlation
with the inflammatory markers. The literature also contains
references to the link between TNF- and leptin (Pi-Sunyer,
2006; Lago et al., 2007). Adiponectin exhibited an inverse
correlation only with CRP. Although it has been suggested
that TNF- inhibits the synthesis of adiponectin (Matsu-
zawa, 2006), we observed no correlation between TNF-
and adiponectin.
The positive correlation between inflammatory markers (es-
pecially CRP) and the indicators of carbohydrates metabo-
lism, as well as their probable link with the development of
insulin resistance and diabetes mellitus, and the negative
correlation between CRP and TNF- with HDL–C provides
evidence of an association between these inflammatory
markers and the development of atherosclerosis.
The expression of PAI1 occurs predominantly and locally in
the endothelium and platelets, and systemically in the liver
and fatty tissue. This expression is influenced by many fac-
tors and plays significant roles in remodelling blood vessels
and thrombotic complications (Taeve et al., 2005). Our ob-
servations show an association between PAI1 with both
obesity and adverse changes in lipid and carbohydrate me-
tabolism. Therefore, PAI1 can be considered a significant
marker for the development of atherosclerosis.
In conclusion, our study shows that leptin levels correlate
with all the studied inflammatory markers. PAI1 and CRP
are the most sensitive integral inflammatory markers. The
roles of TNF- and IL6 in the assessment of CVD risk
should be defined more precisely in future research.
Inflammatory markers provide valuable additional informa-
tion in the assessment of CVD risk. However, because the
various inflammatory markers characterise different inflam-
matory reactions, it is important to determine several factors
simultaneously.
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IEKAISUMA MARÍIERU SAISTÎBA AR KARDIOVASKULÂRO SLIMÎBU KLÎNISKAJIEM UN METABOLAJIEM RISKA
FAKTORIEM
Iekaisumam ir svarîga loma aterosklerozes attîstîbâ. Tomçr galveno iekaisuma maríieru – C-reaktîvâ olbaltuma (CRO), interleikîna 6 (IL6),
audzçja nekrozes faktora alfa (ANF-), plazminogçna aktivatora inhibitora 1 (PAI1) un citu klîniskâ nozîme nav pilnîba skaidra. Simt
pacientiem tika noteikti CRO, IL6, ANF- un PAI1 vienlaicîgi ar klîniskiem parametriem (dzimumu, adipozitâtes râdîtâjiem, asins
spiedienu un sirds frekvenci), kopçjâ holesterîna (KH), zema blîvuma lipoproteînu holesterîna (ZBLH), augsta blîvuma lipoproteînu
holesterîna (ABLH), triglicerîdu (TG), glikozes, insulîna, insulîna rezistences râdîtâja HOMA-IR, adiponektîna un leptîna lîmeòiem. CRO
un PAI1 lîmeòi bija paaugstinâti personâm ar palielinâtu íermeòa masas indeksu (ÍMI) un vçdera apkârtmçru (VA). CRO pozitîvi korelçja
ar ogïhidrâtu metabolisma râdîtâjiem un negatîvi ar KH, ABLH un adiponektinu. PAI1 pozitîvi korelçja ar insulîna lîmeni, HOMA-IR,
leptînu un TG, bet negatîvi ar ABLH. IL6 negatîvi korelçja ar KH, bet ANF- negatîvi korelçja ar ABLH. Bet gan IL6, gan ANF-
pozitîvi korelçja ar leptîna lîmeni. Savukârt TG lîmeni un ogïhidrâtu metabolisma râdîtâjiem, ANF- korelçja tikai sievietçm. CRO un PAI1
ir visjûtîgâkie iekaisuma maríieri, to lîmenis ir augstâks adipozâm personâm.
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